Dr. Ritter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 S Nolen Dr
Southlake, TX 76092Phone+1 817-424-1525Fax+1 817-424-3491
Education & Training
University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 1990 - 1993- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1987 - 1990
University of Texas Southwestern Medical SchoolClass of 1987
Certifications & Licensure
TX State Medical License 1988 - 2026
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- A Study of CDPATH™ to Help Manage and Treat Crohn's Disease Start of enrollment: 2021 Jun 25
Roles: Principal Investigator
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) Start of enrollment: 2024 Jun 12
Roles: Principal Investigator
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease Start of enrollment: 2024 Apr 18
Roles: Principal Investigator
Publications & Presentations
PubMed
- Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study.Hiroshi Nakase, Silvio Danese, Walter Reinisch, Timothy Ritter, Yan Liang
Inflammatory Bowel Diseases. 2024-12-04 - 1 citationsEfficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.Séverine Vermeire, Stefan Schreiber, David T Rubin, Geert D'Haens, Walter Reinisch
The Lancet. Gastroenterology & Hepatology. 2024-12-02 - 1 citationsImpact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, Geert R D'Haens, Julian Panés
Journal of Crohn's & Colitis. 2024-11-04
Press Mentions
Substantial Variation Seen in Ileosigmoid Fistula Management in Crohn’s DiseaseDecember 14th, 2024
Expert: Fatty Liver Disease Is the Next Healthcare EpidemicAugust 19th, 2019- More Real-World Data and New Analyses of Data for REBYOTA® (Fecal Microbiota, Live – Jslm) Presented at IDWeek 2023October 15th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
